All News
Filter News
Found 167 articles
-
Equillium, 9 Meters Biopharma and ABVC Biopharma have something to say about lupus, short bowel syndrome and ADHD.
-
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
9/27/2022
Equillium, Inc. today announced interim results from the Type B portion of the EQUALISE study evaluating itolizumab, a first-in-class anti-CD6 monoclonal antibody selectively targeting the CD6-ALCAM pathway, in patients with lupus nephritis (LN).
-
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
9/15/2022
Equillium, Inc. today announced that an abstract was accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology.
-
Roche acquired privately held Good Therapeutics and its immuno-oncology platforms for $250 million, and Equillium acquired Metacrine and its GI platform in an all-stock deal.
-
Equillium to Acquire Metacrine in All-Stock Transaction
9/6/2022
Equillium, Inc. and Metacrine Inc., announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction.
-
Equillium to Present at Two Upcoming Investor Conferences in September 2022
8/31/2022
Equillium, Inc. announced that it will participate in a fireside chat presentation at the Wells Fargo Healthcare Conference and a corporate presentation at the H.C. Wainwright Annual Global Investment Conference.
-
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
8/15/2022
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2022 and provided an update on its clinical development programs.
-
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
7/28/2022
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit.
-
Patients with Lupus Benefit from COVID-19 Vaccine Booster
7/12/2022
People with systemic lupus erythematosus, or SLE, who received a "booster" dose of SARS-CoV-2 vaccine after full vaccination are roughly half as likely to have a subsequent "breakthrough" COVID-19 infection, a new study shows.
-
Equillium to Present at Two Upcoming Investor Conferences
5/17/2022
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference.
-
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
5/12/2022
Equillium, Inc. announced that the European Hematology Association has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease.
-
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
5/12/2022
Equillium, Inc. announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.
-
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
-
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
5/9/2022
Equillium, Inc. today announced that three posters were presented over the weekend at IMMUNOLOGY2022, the annual meeting of The American Association of Immunologists.
-
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
4/25/2022
Equillium, Inc. today announced that three posters were presented over the weekend at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.
-
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
4/4/2022
Equillium, Inc. announced an oral presentation at the 2022 National Congress of the Italian Society of Experimental Hematology in Rome, Italy.
-
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
3/23/2022
Equillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, announced two oral presentations at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation.
-
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
3/23/2022
Equillium, Inc. announced financial results for the fourth quarter and full year 2021 and provided corporate and clinical development updates.
-
Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease
3/4/2022
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease (aGVHD).
-
Equillium Announces Appointment of Barbara Troupin to Board of Directors
3/1/2022
Equillium, Inc. today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors.